JP2023523682A - B細胞急性リンパ芽球性白血病(b-all)の処置のためのcd22標的化部分 - Google Patents
B細胞急性リンパ芽球性白血病(b-all)の処置のためのcd22標的化部分 Download PDFInfo
- Publication number
- JP2023523682A JP2023523682A JP2022554601A JP2022554601A JP2023523682A JP 2023523682 A JP2023523682 A JP 2023523682A JP 2022554601 A JP2022554601 A JP 2022554601A JP 2022554601 A JP2022554601 A JP 2022554601A JP 2023523682 A JP2023523682 A JP 2023523682A
- Authority
- JP
- Japan
- Prior art keywords
- domain
- car
- cells
- seq
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100038080 B-cell receptor CD22 Human genes 0.000 title claims abstract description 157
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 title claims abstract description 149
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 title claims abstract description 81
- 230000008685 targeting Effects 0.000 title claims description 31
- 238000011282 treatment Methods 0.000 title abstract description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 127
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 85
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 45
- 210000004027 cell Anatomy 0.000 claims description 187
- 230000011664 signaling Effects 0.000 claims description 39
- 230000004068 intracellular signaling Effects 0.000 claims description 36
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 32
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 32
- 230000003834 intracellular effect Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 18
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 15
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 14
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 11
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 10
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 10
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 10
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 claims description 9
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 8
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- -1 CD86 Proteins 0.000 claims description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 6
- 102100037904 CD9 antigen Human genes 0.000 claims description 5
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 5
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 5
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 5
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 5
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 5
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 5
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 5
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 claims description 4
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 abstract description 20
- 108091007433 antigens Proteins 0.000 abstract description 20
- 102000036639 antigens Human genes 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 17
- 239000012528 membrane Substances 0.000 abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 abstract description 7
- 210000001185 bone marrow Anatomy 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 30
- 210000005259 peripheral blood Anatomy 0.000 description 26
- 239000011886 peripheral blood Substances 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 230000002688 persistence Effects 0.000 description 20
- 229920003356 PDX® Polymers 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 238000001990 intravenous administration Methods 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 230000000770 proinflammatory effect Effects 0.000 description 16
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 230000036961 partial effect Effects 0.000 description 13
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 12
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 12
- 230000029918 bioluminescence Effects 0.000 description 12
- 238000005415 bioluminescence Methods 0.000 description 12
- 238000002784 cytotoxicity assay Methods 0.000 description 12
- 231100000263 cytotoxicity test Toxicity 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- 230000026683 transduction Effects 0.000 description 11
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 10
- 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 10
- 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 208000032839 leukemia Diseases 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 108091033409 CRISPR Proteins 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102000000704 Interleukin-7 Human genes 0.000 description 7
- 108010002586 Interleukin-7 Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000013401 experimental design Methods 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 229940100994 interleukin-7 Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000011357 CAR T-cell therapy Methods 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108090000172 Interleukin-15 Proteins 0.000 description 5
- 102000003812 Interleukin-15 Human genes 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 229940127174 UCHT1 Drugs 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000011277 treatment modality Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000002577 cryoprotective agent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 208000037821 progressive disease Diseases 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000002303 tibia Anatomy 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 108700010039 chimeric receptor Proteins 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 101001070329 Geobacillus stearothermophilus 50S ribosomal protein L18 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000000719 anti-leukaemic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- HTCSFFGLRQDZDE-UHFFFAOYSA-N 2-azaniumyl-2-phenylpropanoate Chemical compound OC(=O)C(N)(C)C1=CC=CC=C1 HTCSFFGLRQDZDE-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 101100069853 Caenorhabditis elegans hil-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000610085 Mus musculus Probasin Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 150000003999 cyclitols Chemical class 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000044389 human CD22 Human genes 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 238000002888 pairwise sequence alignment Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Description
患者へ医薬を「投与すること」または患者への医薬「の投与」(およびこの語句の文法的等価物)は、医療専門家による患者への投与であり得るか、または自己投与であり得る直接投与、および/または薬物を処方する行為であり得る間接投与を指す。例えば、患者に医薬を自己投与するように指示するか、または患者に薬物の処方箋を提供する医師が、患者へ薬物を投与している。
説明
[DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGS GSGTDFTLKISRVEAEDLGVYYCWQGTHFPWTFGGGTKLEIKRA]
[EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRISITRDTSKNQYYMQLKSVTTEDTATYYCARYPSPDAMNYWGQGTSVTVSS]
[EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRISITRDTSKNQYYMQLKSVTTEDTATYYCARYPSPDAMNYWGQGTSVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPWTFGGGTKLEIKRA]
[TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC]
[RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR]
[KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL]
(i)VLドメインおよびVHドメインを含むscFvであって、前記VLドメインがLCDR1、LCDR2およびLCDR3ポリペプチドを含み、前記VHドメインがHCDR1、HCDR2およびHCDR3ポリペプチドを含み、LCDR1が配列番号1からなり、LCDR2が配列番号2からなり、LCDR3が配列番号3からなり、HCDR1が配列番号4からなり、HCDR2が配列番号5からなり、HCDR3が配列番号6からなる、scFv;
(ii)配列番号10、または配列番号10に対して95%の配列同一性を有する配列を含む膜貫通ドメイン;
(iii)配列番号11、または配列番号11に対して95%の配列同一性を有する配列を含む細胞内シグナリングドメイン;ならびに
(iv)配列番号12、または配列番号12に対して95%の配列同一性を有する配列を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、前記VLドメインがLCDR1、LCDR2およびLCDR3ポリペプチドを含み、前記VHドメインがHCDR1、HCDR2およびHCDR3ポリペプチドを含み、LCDR1が配列番号1からなり、LCDR2が配列番号2からなり、LCDR3が配列番号3からなり、HCDR1が配列番号4からなり、HCDR2が配列番号5からなり、HCDR3が配列番号6からなる、scFv;
(ii)配列番号10、または配列番号10に対して98%の配列同一性を有する配列を含む膜貫通ドメイン;
(iii)配列番号11、または配列番号11に対して98%の配列同一性を有する配列を含む細胞内シグナリングドメイン;ならびに
(iv)配列番号12、または配列番号12に対して98%の配列同一性を有する配列を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、前記VLドメインがLCDR1、LCDR2およびLCDR3ポリペプチドを含み、前記VHドメインがHCDR1、HCDR2およびHCDR3ポリペプチドを含み、LCDR1が配列番号1からなり、LCDR2が配列番号2からなり、LCDR3が配列番号3からなり、HCDR1が配列番号4からなり、HCDR2が配列番号5からなり、HCDR3が配列番号6からなる、scFv;
(ii)配列番号10、または配列番号10に対して98%の配列同一性を有する配列を含む膜貫通ドメイン;
(iii)配列番号11、または配列番号11に対して99%の配列同一性を有する配列を含む細胞内シグナリングドメイン;ならびに
(iv)配列番号12、または配列番号12に対して99%の配列同一性を有する配列を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、前記VLドメインがLCDR1、LCDR2およびLCDR3ポリペプチドを含み、前記VHドメインがHCDR1、HCDR2およびHCDR3ポリペプチドを含み、LCDR1が配列番号1からなり、LCDR2が配列番号2からなり、LCDR3が配列番号3からなり、HCDR1が配列番号4からなり、HCDR2が配列番号5からなり、HCDR3が配列番号6からなる、scFv;
(ii)配列番号10を含む膜貫通ドメイン;
(iii)配列番号11を含む細胞内シグナリングドメイン;ならびに
(iv)配列番号12を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、前記VLドメインがLCDR1、LCDR2およびLCDR3ポリペプチドを含み、前記VHドメインがHCDR1、HCDR2およびHCDR3ポリペプチドを含み、LCDR1が配列番号1からなり、LCDR2が配列番号2からなり、LCDR3が配列番号3からなり、HCDR1が配列番号4からなり、HCDR2が配列番号5からなり、HCDR3が配列番号6からなる、scFv;
(ii)配列番号10からなる膜貫通ドメイン;
(iii)配列番号11からなる細胞内シグナリングドメイン;ならびに
(iv)配列番号12からなる共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、VLドメインが配列番号7からなり、VHドメインが配列番号8からなる、scFv;
(ii)配列番号10、または配列番号10に対して95%の配列同一性を有する配列を含む膜貫通ドメイン;
(iii)配列番号11、または配列番号11に対して95%の配列同一性を有する配列を含む細胞内シグナリングドメイン;ならびに
(iv)配列番号12、または配列番号12に対して95%の配列同一性を有する配列を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、VLドメインが配列番号23からなり、VHドメインが配列番号22からなる、scFv;
(ii)配列番号10、または配列番号10に対して95%、98%、99%または100%の配列同一性を有する配列を含む膜貫通ドメイン;
(iii)配列番号11、または配列番号11に対して95%、98%、99%または100%の配列同一性を有する配列を含む細胞内シグナリングドメイン;および
(iv)配列番号12、または配列番号12に対して95%、98%、99%または100%の配列同一性を有する配列を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、VLドメインが配列番号21からなり、VHドメインが配列番号20からなる、scFv;
(ii)配列番号10、または配列番号10に対して95%、98%、99%または100%の配列同一性を有する配列を含むかまたはそれからなる膜貫通ドメイン;
(iii)配列番号11、または配列番号11に対して95%、98%、99%または100%の配列同一性を有する配列を含むかまたはそれからなる細胞内シグナリングドメイン;および
(iv)配列番号12、または配列番号12に対して95%、98%、99%または100%の配列同一性を有する配列を含むかそれからなる共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、VLドメインが配列番号7からなり、VHドメインが配列番号8からなる、scFv;
(ii)配列番号10、または配列番号10に対して98%の配列同一性を有する配列を含む膜貫通ドメイン;
(iii)配列番号11、または配列番号11に対して98%の配列同一性を有する配列を含む細胞内シグナリングドメイン;および
(iv)配列番号12、または配列番号12に対して98%の配列同一性を有する配列を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、VLドメインが配列番号7からなり、VHドメインが配列番号8からなる、scFv;
(ii)配列番号10、または配列番号10に対して99%の配列同一性を有する配列を含む膜貫通ドメイン;
(iii)配列番号11、または配列番号11に対して99%の配列同一性を有する配列を含む細胞内シグナリングドメイン;および
(iv)配列番号12、または配列番号12に対して99%の配列同一性を有する配列を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、VLドメインが配列番号7からなり、VHドメインが配列番号8からなる、scFv;
(ii)配列番号10を含む膜貫通ドメイン;
(iii)配列番号11を含む細胞内シグナリングドメイン;および
(iv)配列番号12を含む共刺激シグナリングドメイン。
(i)VLドメインおよびVHドメインを含むscFvであって、VLドメインが配列番号7からなり、VHドメインが配列番号8からなる、scFv;
(ii)配列番号10からなる膜貫通ドメイン;
(iii)配列番号11からなる細胞内シグナリングドメイン;および
(iv)配列番号12からなる共刺激シグナリングドメイン。
[EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRISITRDTSKNQYYMQLKSVTTEDTATYYCARYPSPDAMNYWGQGTSVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPWTFGGGTKLEIKRATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR]
材料および方法
CD22一本鎖可変断片(scFv)の作製
CAR設計およびベクター、レンチウイルス産生およびT細胞形質導入
細胞株
インビトロ細胞傷害性アッセイおよびサイトカイン放出の判定
フローサイトメトリー
B-ALLおよびCAR T細胞のインビボ異種移植モデル
統計解析
結果
CD22.7-CAR T細胞は、インビトロでB-ALL細胞を効率的に排除する
CD22の発現レベルは、B-ALL初代細胞を死滅させる際のCD22.7-CAR T細胞の効率に影響を及ぼす
膜遠位CD22エピトープ指向CAR T細胞は、臨床的に重要な患者由来の異種移植片においてインビボでB-ALL芽球を効率的に排除する
実施例2.イノツズマブおよびCD22に対する新規抗CD22 scFv(クローンhCD22.7)のエピトープのマッピング。
実施例3.B細胞白血病細胞株NALM6を用いた実験
材料および方法
結果
実施例4.急性リンパ芽球性白血病細胞株SEM(CD22陽性)を用いた実験
材料および方法
結果
実施例5.新規抗CD22(クローンhCD22.7)のscFvのヒト化
1.配列ベースの(および構造アシストの)CDRグラフティング;および
2.「脱マウス化(De-murinenization)」。
QVQLQESGPGLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEWIGYISYSGSTYYNPSLKSRITISRDTSKNQYSLKLSSVTTEDTATYYCARYPSPDAMNYWGQGTSVTVSS
DVVMTQTPLTLPVTLGQPASISCKSSQSLLDSDGKTYLNWLQQRPGQSPKRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFWTFGGGTKLEIKRA
QVQLQESGPSLVKPGQTLSLTCSVTGDSITSGYWNWIRQSPGNKLEYMGYISYSGSTYYNPTLKGRISITRDNSSSQYYLQLKSVTSEDTATFYCARYPSPDAMNYWGQGTSVTVSS
DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKLLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEADDLGVYFCWQGTHFWTFGGGTKLEIKRA
Claims (14)
- 配列番号15として記載されるCD22抗原の第1のIg細胞外ドメインの領域に対して結合親和性を有し、VLドメインおよびVHドメインを含む、抗体、F(ab’)2、Fab、scFabまたはscFvであるCD22標的化部分であって、前記VLドメインが配列番号7のみからなり、前記VHドメインが配列番号8のみからなる、CD22標的化部分。
- 前記CD22標的化部分が、VLドメインおよびVHドメインを含むscFvであり、前記VLドメインが配列番号7のみからなり、前記VHドメインが配列番号8からなる、請求項1に記載のCD22標的化部分。
- 前記CD22標的化部分が、配列番号9のみからなるscFvである、請求項2に記載のCD22標的化部分。
- a.請求項1に記載のCD22標的化部分を含む細胞外ドメイン;
b.膜貫通ドメイン;および
c.細胞内シグナリングドメイン
を含む、キメラ抗原受容体(CAR)。 - 前記膜貫通ドメインが、CD28、CD3、CD45、CD4、CD8、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137、またはCD154の膜貫通ドメインを含む、請求項4に記載のCAR。
- 前記膜貫通ドメインがCD8の膜貫通ドメインを含む、請求項5に記載のCAR。
- 前記細胞内シグナリングドメインが、CD3ζ、FcRγ、CD3γ、CD3δ、CD3ε、CD5、CD22、CD79a、CD79bまたはCD66bの細胞内ドメインを含む、請求項4から6のいずれか一項に記載のCAR。
- 前記細胞内シグナリングドメインがCD3ζの細胞内ドメインを含む、請求項7に記載のCAR。
- 前記CARが共刺激シグナリングドメインをさらに含み、好ましくは、前記共刺激シグナリングドメインが、CD27、CD28、CD137、CD134、CD30、CD40、リンパ球機能関連抗原1(LFA-1)、CD2、CD7、LIGHT、NKG2C、またはCD276の細胞内ドメインを含む、請求項4から8のいずれか一項に記載のCAR。
- 前記共刺激シグナリングドメインがCD137の細胞内ドメインを含む、請求項9に記載のCAR。
- 前記CD22標的化部分がscFVであり、好ましくは、前記scFVが、配列番号7のみからなるVLドメインおよび配列番号8のみからなるVHドメインを含む、請求項4から10のいずれか一項に記載のCAR。
- 請求項4から11のいずれか一項に記載のCARをコードする核酸。
- 請求項12に記載の核酸を含むT細胞。
- CD22陽性がんを処置する方法において使用するための、請求項13に記載の細胞または請求項1から3のいずれか一項に記載のCD22標的化部分であって、前記方法が、前記細胞または組成物を、それを必要とする患者に投与することを含み、前記CD22陽性がんが、B細胞急性リンパ芽球性白血病(B-ALL)、より具体的にはCD19-B-ALLの再発である、細胞またはCD22標的化部分。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20382175.6 | 2020-03-11 | ||
EP20382175 | 2020-03-11 | ||
PCT/EP2021/056262 WO2021180890A1 (en) | 2020-03-11 | 2021-03-11 | Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all) |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023523682A true JP2023523682A (ja) | 2023-06-07 |
Family
ID=69810766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022554601A Pending JP2023523682A (ja) | 2020-03-11 | 2021-03-11 | B細胞急性リンパ芽球性白血病(b-all)の処置のためのcd22標的化部分 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230139885A1 (ja) |
EP (1) | EP4117789A1 (ja) |
JP (1) | JP2023523682A (ja) |
CN (1) | CN115843255A (ja) |
AU (1) | AU2021233158A1 (ja) |
CA (1) | CA3174638A1 (ja) |
MX (1) | MX2022011289A (ja) |
WO (1) | WO2021180890A1 (ja) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
ES2330052T3 (es) | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
CA3224507A1 (en) * | 2014-12-24 | 2016-06-30 | Autolus Limited | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
RU2021121771A (ru) * | 2015-04-08 | 2022-01-12 | Новартис Аг | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19 |
GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
-
2021
- 2021-03-11 AU AU2021233158A patent/AU2021233158A1/en active Pending
- 2021-03-11 WO PCT/EP2021/056262 patent/WO2021180890A1/en unknown
- 2021-03-11 US US17/910,564 patent/US20230139885A1/en active Pending
- 2021-03-11 CN CN202180034975.4A patent/CN115843255A/zh active Pending
- 2021-03-11 MX MX2022011289A patent/MX2022011289A/es unknown
- 2021-03-11 EP EP21710318.3A patent/EP4117789A1/en active Pending
- 2021-03-11 JP JP2022554601A patent/JP2023523682A/ja active Pending
- 2021-03-11 CA CA3174638A patent/CA3174638A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021233158A1 (en) | 2022-09-29 |
WO2021180890A1 (en) | 2021-09-16 |
MX2022011289A (es) | 2022-12-08 |
CN115843255A (zh) | 2023-03-24 |
US20230139885A1 (en) | 2023-05-04 |
AU2021233158A2 (en) | 2023-04-06 |
EP4117789A1 (en) | 2023-01-18 |
CA3174638A1 (en) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11034766B2 (en) | Anti-B7-H6 antibody, fusion proteins, and methods of using the same | |
US10040865B2 (en) | T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2 | |
US20210137977A1 (en) | Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy | |
JP2021094037A (ja) | 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法 | |
AU2010299895B2 (en) | Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses | |
US20220143085A1 (en) | Car t-cells for the treatment of cd1a-positive cancer | |
JP2022513691A (ja) | B細胞成熟抗原を標的とするキメラ抗原受容体およびその使用方法 | |
WO2022216965A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
Kudva et al. | Immunotherapy for neuroblastoma | |
KR20230121114A (ko) | 암의 치료를 위한 다중특이적 항체 | |
Ren‐Heidenreich et al. | Redirected T‐cell cytotoxicity to epithelial cell adhesion molecule‐overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model | |
EP4007777B1 (en) | Car t-cells against bcma for the treatment of multiple myeloma | |
US20230151094A1 (en) | Chimeric antigen receptors targeting cd33 | |
JP2024513262A (ja) | Nkp46及びcd38を標的とする二重特異性抗体、並びにその使用方法 | |
US20230139885A1 (en) | Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all) | |
EP4234582A1 (en) | Humanized cd1a targeting moiety for the treatment of cd1a-positive cancer | |
WO2023030539A1 (en) | Anti-gpc3 chimeric antigen receptor and methods of use thereof | |
CN113735973B (zh) | 一种抗SIRPα抗体及其应用 | |
WO2023161530A1 (en) | HUMANIZED CD1a TARGETING MOIETY FOR THE TREATMENT OF CD1A-POSITIVE CANCER | |
WO2022164886A2 (en) | Chimeric antigen receptors targeting cd20 | |
CN117858719A (zh) | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20230112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230220 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240409 |